

Xiao-Long Fu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1498353/publications.pdf>

Version: 2024-02-01

97
papers

1,527
citations

394421

19
h-index

414414

32
g-index

103
all docs

103
docs citations

103
times ranked

2034
citing authors

#	ARTICLE	IF	CITATIONS
1	Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling. <i>European Radiology</i> , 2019, 29, 4742-4750.	4.5	121
2	Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. , 2022, 10, e004291.		77
3	Number of Negative Lymph Nodes is Associated with Survival in Thoracic Esophageal Squamous Cell Carcinoma Patients Undergoing Three-Field Lymphadenectomy. <i>Annals of Surgical Oncology</i> , 2014, 21, 2857-2863.	1.5	76
4	Patterns of Failure after Radical Surgery among Patients with Thoracic Esophageal Squamous Cell Carcinoma: Implications for the Clinical Target Volume Design of Postoperative Radiotherapy. <i>PLoS ONE</i> , 2014, 9, e97225.	2.5	67
5	KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. <i>Future Oncology</i> , 2021, 17, 1143-1153.	2.4	63
6	Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by 18FDG-PET/CT for esophageal cancer. <i>Radiotherapy and Oncology</i> , 2015, 114, 195-200.	0.6	60
7	Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 347-353.	1.1	50
8	Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 979-986.	2.0	45
9	Phase 2 Study of Accelerated Hypofractionated Thoracic Radiation Therapy and Concurrent Chemotherapy in Patients With Limited-Stage Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 517-523.	0.8	45
10	Patterns of Local-Regional Failure in Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer Cases: Implications for Postoperative Radiation Therapy Clinical Target Volume Design. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1100-1107.	0.8	39
11	Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 7227-7240.	1.8	38
12	A phase II trial of accelerated hypofractionated three-dimensional conformal radiation therapy in locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2011, 98, 304-308.	0.6	36
13	The Role of PET-Based Radiomic Features in Predicting Local Control of Esophageal Cancer Treated with Concurrent Chemoradiotherapy. <i>Scientific Reports</i> , 2018, 8, 9902.	3.3	35
14	Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1349-1358.	0.8	35
15	Nodal Skip Metastasis is not a Predictor of Survival in Thoracic Esophageal Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 3052-3058.	1.5	32
16	Detection of epithelial growth factor receptor (EGFR) mutations on CT images of patients with lung adenocarcinoma using radiomics and/or multi-level residual convolutionary neural networks. <i>Journal of Thoracic Disease</i> , 2018, 10, 6624-6635.	1.4	31
17	The pivotal role of <sc>DNA</sc> methylation in the radio-sensitivity of tumor radiotherapy. <i>Cancer Medicine</i> , 2018, 7, 3812-3819.	2.8	31
18	The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume. <i>BMC Cancer</i> , 2015, 15, 348.	2.6	26

#	ARTICLE	IF	CITATIONS
19	Clinical significance of age at diagnosis among young non-small cell lung cancer patients under 40 years old: a population-based study. <i>Oncotarget</i> , 2015, 6, 44963-44970.	1.8	25
20	Is involved-field radiotherapy based on CT safe for patients with limited-stage small-cell lung cancer?. <i>Radiotherapy and Oncology</i> , 2012, 102, 258-262.	0.6	23
21	Tissue-based quantitative proteomics to screen and identify the potential biomarkers for early recurrence/metastasis of esophageal squamous cell carcinoma. <i>Cancer Medicine</i> , 2018, 7, 2504-2517.	2.8	22
22	Predicting the Value of Adjuvant Therapy in Esophageal Squamous Cell Carcinoma by Combining the Total Number of Examined Lymph Nodes with the Positive Lymph Node Ratio. <i>Annals of Surgical Oncology</i> , 2019, 26, 2367-2374.	1.5	21
23	Phosphorylated AKT1 is associated with poor prognosis in esophageal squamous cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 95.	8.6	19
24	High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis. <i>Oncotarget</i> , 2015, 6, 18674-18682.	1.8	19
25	Identifying epidermal growth factor receptor mutation status in patients with lung adenocarcinoma by three-dimensional convolutional neural networks. <i>British Journal of Radiology</i> , 2018, 91, 20180334.	2.2	18
26	Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection. <i>Frontiers in Oncology</i> , 2021, 11, 711206.	2.8	18
27	Characteristics of the local recurrence pattern after curative resection and values in target region delineation in postoperative radiotherapy for lower thoracic esophageal squamous cell cancer. <i>Thoracic Cancer</i> , 2017, 8, 630-633.	1.9	16
28	Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge—a narrative review. <i>Translational Lung Cancer Research</i> , 2020, 9, 2120-2136.	2.8	16
29	Proposed revision of CT-based cervical and thoracic lymph node levels for esophageal cancer in UICC 7th version. <i>Radiotherapy and Oncology</i> , 2014, 113, 175-181.	0.6	15
30	Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer. <i>Radiation Oncology</i> , 2017, 12, 51.	2.7	15
31	Study for reducing lung dose of upper thoracic esophageal cancer radiotherapy by auto-planning: volumetric-modulated arc therapy vs intensity-modulated radiation therapy. <i>Medical Dosimetry</i> , 2018, 43, 243-250.	0.9	15
32	Implementation Strategy of a CNN Model Affects the Performance of CT Assessment of EGFR Mutation Status in Lung Cancer Patients. <i>IEEE Access</i> , 2019, 7, 64583-64591.	4.2	15
33	microRNA-messenger RNA regulatory network of esophageal squamous cell carcinoma and the identification of miR-1 as a biomarker of patient survival. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 12259-12272.	2.6	14
34	Clinical impact of the tumor immune microenvironment in completely resected stage IIIA(N2) non-small cell lung cancer based on an immunological score approach. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098497.	3.2	14
35	The radiation techniques of tomotherapy & intensity-modulated radiation therapy applied to lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 265-74.	2.8	14
36	Postoperative Radiotherapy for Resected Stage IIIA-N2 Non-small-cell Lung Cancer: A Population-Based Time-Trend Study. <i>Lung</i> , 2019, 197, 741-751.	3.3	13

#	ARTICLE	IF	CITATIONS
37	On the optimal number of dose-limiting shells in the SBRT auto-planning design for peripheral lung cancer. <i>Journal of Applied Clinical Medical Physics</i> , 2020, 21, 134-142.	1.9	12
38	Automatic segmentation of lung tumors on CT images based on a 2D & 3D hybrid convolutional neural network. <i>British Journal of Radiology</i> , 2021, 94, 20210038.	2.2	12
39	Tolerance and dose-volume relationship of intrathoracic stomach irradiation after esophagectomy for patients with thoracic esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2015, 6, 32220-32227.	1.8	12
40	PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells. <i>Oncotarget</i> , 2016, 7, 49384-49396.	1.8	12
41	The effect of bioequivalent radiation dose on survival of patients with limited-stage small-cell lung cancer. <i>Radiation Oncology</i> , 2011, 6, 50.	2.7	11
42	The positive role of vitronectin in radiation induced lung toxicity: the in vitro and in vivo mechanism study. <i>Journal of Translational Medicine</i> , 2018, 16, 100.	4.4	11
43	Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio associations with heart and body dose and their effects on patient outcomes in locally advanced non-small cell lung cancer treated with definitive radiotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 1996-2007.	2.8	11
44	High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy. <i>OncoTargets and Therapy</i> , 2015, 9, 117.	2.0	10
45	Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , 2020, 21, 534-544.	2.6	10
46	Quantitative analysis of tumor shrinkage due to chemotherapy and its implication for radiation treatment planning in limited-stage small-cell lung cancer. <i>Radiation Oncology</i> , 2013, 8, 216.	2.7	9
47	Timing of thoracic radiotherapy is more important than dose intensification in patients with limited-stage small cell lung cancer: a parallel comparison of two prospective studies. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 172-181.	2.0	9
48	Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2059-2073.	2.8	9
49	GATA6 Exerts Potent Lung Cancer Suppressive Function by Inducing Cell Senescence. <i>Frontiers in Oncology</i> , 2020, 10, 824.	2.8	9
50	Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 615167.	2.8	8
51	Radiosensitivity-Specific Proteomic and Signaling Pathway Network of Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 529-541.	0.8	8
52	Sequential Chemoradiotherapy with Accelerated Hypofractionated Radiotherapy Compared to Concurrent Chemoradiotherapy with Standard Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer. <i>Technology in Cancer Research and Treatment</i> , 2014, 13, 269-275.	1.9	7
53	Analyses of distribution and dosimetry of brain metastases in small cell lung cancer with relation to the neural stem cell regions: feasibility of sparing the hippocampus in prophylactic cranial irradiation. <i>Radiation Oncology</i> , 2017, 12, 118.	2.7	7
54	Deep learning-based automatic delineation of the hippocampus by MRI: geometric and dosimetric evaluation. <i>Radiation Oncology</i> , 2021, 16, 12.	2.7	7

#	ARTICLE	IF	CITATIONS
55	Predicting Tyrosine Kinase Inhibitor Treatment Response in Stage IV Lung Adenocarcinoma Patients With EGFR Mutation Using Model-Based Deep Transfer Learning. <i>Frontiers in Oncology</i> , 2021, 11, 679764.	2.8	7
56	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018, 7, 428-436.	2.8	7
57	Clinical significance of age at diagnosis among patients with thymic epithelial tumors: a population-based study. <i>Aging</i> , 2020, 12, 4815-4821.	3.1	7
58	Lung cancer subtype classification using histopathological images based on weakly supervised multi-instance learning. <i>Physics in Medicine and Biology</i> , 2021, 66, 235013.	3.0	7
59	PA-MSHA inhibits proliferation and induces apoptosis in human non-small cell lung cancer cell lines with different genotypes. <i>Molecular Medicine Reports</i> , 2016, 14, 5369-5376.	2.4	6
60	A novel IMRT planning study by using the fixed-jaw method in the treatment of peripheral lung cancer with mediastinal lymph node metastasis. <i>Medical Dosimetry</i> , 2018, 43, 46-54.	0.9	6
61	Risk factors of brain metastases as initial failure in completely resected stage IIIA(N2) non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 374-374.	1.7	6
62	Predictive model of the first failure pattern in patients receiving definitive chemoradiotherapy for inoperable locally advanced non-small cell lung cancer (LA-NSCLC). <i>Radiation Oncology</i> , 2020, 15, 43.	2.7	6
63	A Novel Anticancer Therapeutic Strategy to Target Autophagy Accelerates Radiation-Associated Atherosclerosis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 540-552.	0.8	6
64	Prognostic index for estimating the survival benefit of postoperative radiotherapy in pathologic N2 non-small cell lung cancer: A real-world validation study. <i>Lung Cancer</i> , 2021, 156, 100-108.	2.0	6
65	Biomarkers for the prediction of esophageal cancer neoadjuvant chemoradiotherapy response: A systemic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 167, 103466.	4.4	6
66	Difference in failure patterns of pT3-4N0-3M0 esophageal cancer treated by surgery vs surgery plus radiotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 1172-1181.	2.0	6
67	Prognostic value of EGFR family expression in lymph node-negative esophageal squamous cell carcinoma patients. <i>Pathology Research and Practice</i> , 2018, 214, 1017-1023.	2.3	4
68	The role of prophylactic cranial irradiation in surgically resected combined small cell lung cancer: a retrospective study. <i>Journal of Thoracic Disease</i> , 2018, 10, 3418-3427.	1.4	4
69	Intensity Modulated Radiation Therapy for Pleural Recurrence of Thymoma: A Prospective Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 775-782.	0.8	4
70	Predicting Malignancy and Invasiveness of Pulmonary Subsolid Nodules on CT Images Using Deep Learning. <i>Frontiers in Oncology</i> , 2021, 11, 700158.	2.8	4
71	Dosimetric Comparison, Treatment Efficiency Estimation, and Biological Evaluation of Popular Stereotactic Radiosurgery Options in Treating Single Small Brain Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 716152.	2.8	4
72	A nomogram based on phosphorylated AKT1 for predicting locoregional recurrence in patients with oesophageal squamous cell carcinoma. <i>Journal of Cancer</i> , 2017, 8, 3755-3763.	2.5	3

#	ARTICLE	IF	CITATIONS
73	Radiation-induced lung injury patterns and the misdiagnosis after SBRT of lung cancer. <i>European Journal of Radiology</i> , 2019, 121, 108708.	2.6	3
74	Expression and prognostic value of FOXP1 in esophageal squamous cell carcinoma. <i>Pathology Research and Practice</i> , 2019, 215, 152645.	2.3	3
75	Long-term follow-up of a phase I/II trial of radiation dose escalation by simultaneous integrated boost for locally advanced esophageal squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2021, 159, 190-196.	0.6	3
76	Patterns of Failure in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2021, 11, 724722.	2.8	3
77	A novel CRT+IMRT+combined (Co-CRIM) planning technique for peripheral lung stereotactic body radiotherapy in pinnacle treatment planning system. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 97-107.	1.9	3
78	A novel specific grading standard study of auto-segmentation of organs at risk in thorax: subjective+objective-combined grading standard. <i>BioMedical Engineering OnLine</i> , 2021, 20, 54.	2.7	2
79	Adjuvant chemotherapy improves survival outcomes after complete resection of thymic squamous cell carcinoma: a retrospective study of 116 patients. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2021, 33, 550-556.	1.1	2
80	The Plasma Levels and Polymorphisms of Vitronectin Predict Radiation Pneumonitis in Patients With Lung Cancer Receiving Thoracic Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 757-765.	0.8	2
81	Lymph Node Parameters Predict Adjuvant Chemoradiotherapy Efficacy and Disease-Free Survival in Pathologic N2 Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 736892.	2.8	2
82	Effective Radiotherapy in Tracheobronchial Adenoid Cystic Carcinoma With Positive Surgical Margin. <i>Annals of Thoracic Surgery</i> , 2021, 112, 1585-1592.	1.3	2
83	Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer. <i>BMC Cancer</i> , 2022, 22, 96.	2.6	2
84	Bevacizumab in combination with paclitaxel and platinum for previously treated advanced thymic epithelial tumors. <i>Medical Oncology</i> , 2022, 39, 25.	2.5	2
85	A decision support framework for postoperative radiotherapy in patients with pathological N2 non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2022, 173, 313-318.	0.6	2
86	Primary carcinomas of the trachea: Natural history, treatment and results. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2005, 1, 41-46.	1.1	1
87	Evaluation of IGRT-Induced Imaging Doses and Secondary Cancer Risk for SBRT Early Lung Cancer Patients In Silico Study. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110164.	1.9	1
88	Individualized Fraction Regimen of SBRT Patients With Non-Small Cell Lung Cancer Based on Uncomplicated and Cancer-Free Control Probability. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110119.	1.9	1
89	PS02.033: SIMULTANEOUS INTEGRATED BOOSTING RADIATION DOSE IN UNRESECTABLE THORACIC ESOPHAGEAL CANCER: LONG-TERM OUTCOMES OF A PHASE I/II TRIAL. <i>Ecological Management and Restoration</i> , 2018, 31, 129-129.	0.4	0
90	RA04.05: PREVALENCE OF LYMPH-NODE METASTASIS IN T1B ESOPHAGEAL SQUAMOUS CELL CANCER: IMPLICATIONS FOR ADDITIONAL RADIOTHERAPY DESIGN FOLLOWING ENDOSCOPIC SUBMUCOSAL DISSECTION. <i>Ecological Management and Restoration</i> , 2018, 31, 26-26.	0.4	0

#	ARTICLE	IF	CITATIONS
91	PS02.036: FAILURE PATTERNS AND LATE TOXICITIES OF CONCURRENT CHEMORADIOTHERAPY FOR CERVICAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA: FROM A PROSPECTIVE OBSERVATIONAL STUDY. <i>Ecological Management and Restoration</i> , 2018, 31, 130-130.	0.4	0
92	Identification of differentially expressed proteins in the locoregional recurrent esophageal squamous cell carcinoma by quantitative proteomics. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 991-1006.	1.4	0
93	Dosimetric effect of intensity-modulated radiation therapy for postoperative non-small cell lung cancer with and without air cavity in the planning target volume. <i>Medical Dosimetry</i> , 2022, 47, 32-37.	0.9	0
94	Detailed Analysis and Radiomic Prediction of First Progression Sites of First-Line Targeted Therapy for EGFR-Mutant Lung Adenocarcinoma Patients With Systemic Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 757892.	2.8	0
95	A prospective phase II clinical study of concurrent chemoradiotherapy for 92 cases cervical esophageal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15072-e15072.	1.6	0
96	Concurrent chemoradiotherapy with S-1 in elderly patients with esophageal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15074-e15074.	1.6	0
97	Serum NSE is Early Marker of Transformed Neuroendocrine Tumor After EGFR-TKI Treatment of Lung Adenocarcinoma. <i>Cancer Management and Research</i> , 2022, Volume 14, 1293-1302.	1.9	0